Experience with the routine use of electronic patient-reported outcome measures for patients with lung cancer
Authors
Crockett, C.Price, James
Pham, Mai
Abdulwahid, Danya
Bayman, Neil A
Blackhall, Fiona H
Bostock, Layla
Califano, Raffaele
Chan, Clara
Coote, Joanna H
Cove-Smith, Laura
Eaton, Marie
Fenemore, Jackie
Gomes, Fabio
Harris, Maggie A
Halkyard, Emma
Hughes, Sarah
Lindsay, Colin R
Neal, Hilary
McEntee, Delyth
Pemberton, Laura S
Sheikh, Hamid Y
Summers, Yvonne J
Taylor, Paul
Woolf, David K
Yorke, Janelle
Faivre-Finn, Corinne
Affiliation
Northern Ireland Cancer Centre, Belfast, United Kingdom.Issue Date
2023
Metadata
Show full item recordAbstract
Purpose: The Christie NHS Foundation Trust launched their electronic patient-reported outcome measures (ePROMs) service in January 2019 in the routine clinical setting. The lung cancer questionnaires consist of 14 symptom items, adapted from the Common Terminology Criteria for Adverse Events (version 5.0) and the EuroQol EQ-5D-5L quality-of-life (QoL) tool. Patients with lung cancer are invited to complete questionnaires assessing their symptoms and QoL using an online platform. Methods: The ePROM responses and clinical, pathologic, and treatment data for patients who completed the questionnaires between January 2019 and December 2020 were extracted from electronic medical records. The symptom and QoL scores of patients who completed baseline pretreatment ePROMs and also those who completed ePROMs pre- and postpalliative lung systemic anticancer therapy (SACT) or radical thoracic radiotherapy were evaluated. Pretreatment questionnaires were analyzed according to age, Eastern Cooperative Oncology Group performance status (ECOG PS), and Adult Comorbidity Evaluation-27 (ACE-27) comorbidity score. Results: One thousand four hundred eighty patients with lung cancer were included. There were no statistically significant differences in symptoms and QoL scores between age groups. Cough (P = .006) and EQ-5D-5L mobility scores (P = .006) were significantly worse for patients with an ECOG PS of 0-1. Dyspnea (P = .035), hemoptysis (P = .023), nausea (P = .041), mobility (P = .004), and self-care (P = .0420) were significantly worse for those with higher ACE-27 scores (2-3 v 0-1). Palliative SACT was associated with a significant improvement in cough (P < .001) and hemoptysis (P = .025), but significantly negatively affected mobility (P = .013). Patients receiving radical thoracic radiotherapy reported a significant improvement in hemoptysis (P = .042) but worse pain (P = .002) and fatigue (P = .01). Other changes in symptom and QoL scores were not significant. Conclusion: The symptoms and QoL reported at baseline and before and after both palliative SACT and radical thoracic radiotherapy are clinically relevant and meaningful. We have demonstrated that routine implementation of ePROMs into clinical practice is feasible and can inform clinical practice and future research.Citation
Crockett C, Price J, Pham M, Abdulwahid D, Bayman N, Blackhall F, et al. Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer. JCO clinical cancer informatics. 2023 Apr;7:e2200150. PubMed PMID: 37071029. Epub 2023/04/19. eng.Journal
JCO Clinical Cancer InformaticsDOI
10.1200/cci.22.00150PubMed ID
37071029Additional Links
https://dx.doi.org/10.1200/cci.22.00150Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/cci.22.00150
Scopus Count
Collections
Related articles
- Patient and clinician-reported experiences of using electronic patient reported outcome measures (ePROMs) as part of routine cancer care.
- Authors: Payne A, Horne A, Bayman N, Blackhall F, Bostock L, Chan C, Coote J, Eaton M, Fenemore J, Gomes F, Halkyard E, Harris M, Lindsay C, McEntee D, Neal H, Pemberton L, Sheikh H, Woolf D, Price J, Yorke J, Faivre-Finn C
- Issue date: 2023 May 4
- Electronic Patient-Reported Outcome Measures in Radiation Oncology: Initial Experience After Workflow Implementation.
- Authors: Hauth F, Bizu V, App R, Lautenbacher H, Tenev A, Bitzer M, Malek NP, Zips D, Gani C
- Issue date: 2019 Jul 24
- Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
- Authors: Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC
- Issue date: 2013 Feb
- Improving the Understanding and Managing of the Quality of Life of Patients With Lung Cancer With Electronic Patient-Reported Outcome Measures: Scoping Review.
- Authors: García Abejas A, Serra Trullás A, Sobral MA, Canelas D, Leite Costa F, Salvador Verges À
- Issue date: 2023 May 3
- Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer.
- Authors: Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Lamers RJ, Slotman BJ, Wouters EF
- Issue date: 2001 Apr 15